Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions

Watabe, Tadashi; Naka, Sadahiro; Tatsumi, Mitsuaki; Kamiya, Takashi; Kimura, Toru; Shintani, Yasushi; Abe, Kaori; Miyake, Tomohiro; Shimazu, Kenzo; Kobayashi, Shogo; Kurokawa, Yukinori; Eguchi, Hidetoshi; Doki, Yuichiro; Inohara, Hidenori; Kato, Hiroki; Mori, Yuriko; Cardinale, Jens; Giesel, Frederik L.

doi:https://doi.org/10.2967/jnumed.123.265486

Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions

Watabe, Tadashi; Naka, Sadahiro; Tatsumi, Mitsuaki et al.

Journal of Nuclear Medicine, 2023, 64(8), 1225-1231

Number of Access:3,320（2025-07-28 20:05 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/92496

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
JNuclMed_64_8_1225	pdf	None	1.01 MB	261	2023.09.08

Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
Creator	NRID 1000090648932 1000090648932 ORCID 0000-0001-8658-2395 0000-0001-8658-2395 researchmap permalink twosaka2018 twosaka2018 Scopus Author ID 57421862900 57421862900 CreatorName Watabe, Tadashi
	NRID 1000060599843 1000060599843 researchmap permalink _sada_ _sada_ CreatorName Naka, Sadahiro
	NRID 1000060397700 1000060397700 ORCID 0000-0003-1778-0421 0000-0003-1778-0421 researchmap permalink mtatsumi mtatsumi Scopus Author ID 7102266657 7102266657 CreatorName Tatsumi, Mitsuaki
	NRID 1000080550764 1000080550764 CreatorName Kamiya, Takashi
	NRID 1000090580796 1000090580796 ORCID 0000-0003-4504-232X 0000-0003-4504-232X researchmap permalink toru_kimura toru_kimura CreatorName Kimura, Toru
	NRID 1000090572983 1000090572983 researchmap permalink shintani6384 shintani6384 Scopus Author ID 7103142734 7103142734 CreatorName Shintani, Yasushi
	NRID 1000080587593 1000080587593 researchmap permalink AbeKaori AbeKaori Scopus Author ID 57189054847 57189054847 CreatorName Abe, Kaori
	NRID 1000000636110 1000000636110 ORCID 0000-0002-9362-9822 0000-0002-9362-9822 researchmap permalink tomohiromiyake tomohiromiyake Scopus Author ID 55165894400 55165894400 CreatorName Miyake, Tomohiro
	NRID 1000030448039 1000030448039 researchmap permalink _-23f _-23f Scopus Author ID 7005224756 7005224756 CreatorName Shimazu, Kenzo
	NRID 1000030452436 1000030452436 researchmap permalink 30452436 30452436 Scopus Author ID 7405376089 7405376089 ORCID 0000-0002-8828-1067 0000-0002-8828-1067 CreatorName Kobayashi, Shogo
	NRID 1000010470197 1000010470197 researchmap permalink krkw krkw Scopus Author ID 7202562410 7202562410 CreatorName Kurokawa, Yukinori
	NRID 1000090542118 1000090542118 researchmap permalink abcdabcdabcd abcdabcdabcd Scopus Author ID 7101627772 7101627772 CreatorName Eguchi, Hidetoshi
	NRID 1000020291445 1000020291445 researchmap permalink ydoki3251 ydoki3251 Scopus Author ID 7006390687 7006390687 CreatorName Doki, Yuichiro
	NRID 1000000273657 1000000273657 researchmap permalink read0046473 read0046473 Scopus Author ID 7004501837 7004501837 CreatorName Inohara, Hidenori
	NRID 1000020448054 1000020448054 researchmap permalink kato-h kato-h Scopus Author ID 55585587900 55585587900 CreatorName Kato, Hiroki
	CreatorName Mori, Yuriko
	CreatorName Cardinale, Jens
	CreatorName Giesel, Frederik L.
Subject	cancer-associated fibroblast
	fibroblast activation protein
	oncology
	PET
	[18F]FAPI-74
Description	This research was originally published in JNM. Tadashi Watabe, Sadahiro Naka, Mitsuaki Tatsumi et.al. Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions. J Nucl Med. 2023, 64(8), 1225-1231. © SNMMI.
Abstract	The 18F-labeled fibroblast activation protein inhibitor (FAPI) [18F]FAPI- 74 has the benefit of a higher synthetic yield and better image resolution than 68Ga-labeled FAPI. We preliminarily evaluated the diagnostic performance of [18F]FAPI-74 PET in patients with various histopathologically confirmed cancers or suspected malignancies. Methods: We enrolled 31 patients (17 men and 14 women) with lung cancer (n = 7), breast cancer (n = 5), gastric cancer (n = 5), pancreatic cancer (n = 3), other cancers (n = 5), and benign tumors (n = 6). Twenty-seven of the 31 patients were treatment-naïve or preoperative, whereas recurrence was suspected in the remaining 4 patients. Histopathologic confirmation was obtained for the primary lesions of 29 of the 31 patients. In the remaining 2 patients, the final diagnosis was based on the clinical course. [18F]FAPI-74 PET scanning was performed 60min after the intravenous injection of [18F]FAPI-74 (240631 MBq). The [18F]FAPI-74 PET images were compared between the primary or local recurrent lesions of malignant tumors (n = 21) and nonmalignant lesions (n 5 8: type-B1 thymomas, granuloma, solitary fibrous tumor, and postoperative or posttherapeutic changes). The uptake and number of detected lesions on [18F]FAPI-74 PET were also compared with those on [18F]FDG PET for available patients (n = 19). Results: [18F]FAPI-74 PET showed higher uptake in primary lesions of various cancers than in nonmalignant lesions (median SUVmax, 9.39 [range, 1.83-25.28] vs. 3.49 [range, 2.21-15.58]; P = 0.053), but some of the nonmalignant lesions showed high uptake. [18F]FAPI-74 PET also showed significantly higher uptake than [18F]FDG PET (median SUVmax, 9.44 [range, 2.50-25.28] vs. 5.45 [range, 1.22-15.06] in primary lesions [P 5 0.010], 8.86 [range, 3.51-23.33] vs. 3.84 [range, 1.01-9.75] in lymph node metastases [P 5 0.002], and 6.39 [range, 0.55-12.78] vs. 1.88 [range, 0.73-8.35] in other metastases [P 5 0.046], respectively). In 6 patients, [18F]FAPI-74 PET detected more metastatic lesions than [18F]FDG PET. Conclusion: [18F]FAPI-74 PET showed higher uptake and detection rates in primary and metastatic lesions than did [18F]FDG PET. [18F]FAPI-74 PET is a promising novel diagnostic modality for various tumors, especially for precise staging before treatment, including characterization of tumor lesions before surgery. Moreover, 18F-labeled FAPI ligand might serve a higher demand in clinical care in the future.
Publisher	Society of Nuclear Medicine Inc.
Source Title	Journal of Nuclear Medicine
Volume (Issue)	64(8)
Page	1225-1231
Date of Issued	2023-06-02
Language	English
Handle URL	https://hdl.handle.net/11094/92496
PISSN	01615505
eISSN	2159662X
NCID	AA00703684
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.2967/jnumed.123.265486
Access Rights	open access
CopyRight	© 2023 by the Society of Nuclear Medicine andMolecular Imaging.
CopyRight	This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Journal of Nuclear Medicine. 2023, 64(8), p. 1225-1231
DC.title	Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
DC.creator	Watabe, Tadashi
	Naka, Sadahiro
	Tatsumi, Mitsuaki
	Kamiya, Takashi
	Kimura, Toru
	Shintani, Yasushi
	Abe, Kaori
	Miyake, Tomohiro
	Shimazu, Kenzo
	Kobayashi, Shogo
	Kurokawa, Yukinori
	Eguchi, Hidetoshi
	Doki, Yuichiro
	Inohara, Hidenori
	Kato, Hiroki
	Mori, Yuriko
	Cardinale, Jens
	Giesel, Frederik L.
DC.publisher	Society of Nuclear Medicine Inc.
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2023-06-02
DC.identifier	https://doi.org/10.2967/jnumed.123.265486
DC.subject	cancer-associated fibroblast
	fibroblast activation protein
	oncology
	PET
	[18F]FAPI-74
DC.description	This research was originally published in JNM. Tadashi Watabe, Sadahiro Naka, Mitsuaki Tatsumi et.al. Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions. J Nucl Med. 2023, 64(8), 1225-1231. © SNMMI.
DCTERMS.abstract	The 18F-labeled fibroblast activation protein inhibitor (FAPI) [18F]FAPI- 74 has the benefit of a higher synthetic yield and better image resolution than 68Ga-labeled FAPI. We preliminarily evaluated the diagnostic performance of [18F]FAPI-74 PET in patients with various histopathologically confirmed cancers or suspected malignancies. Methods: We enrolled 31 patients (17 men and 14 women) with lung cancer (n = 7), breast cancer (n = 5), gastric cancer (n = 5), pancreatic cancer (n = 3), other cancers (n = 5), and benign tumors (n = 6). Twenty-seven of the 31 patients were treatment-naïve or preoperative, whereas recurrence was suspected in the remaining 4 patients. Histopathologic confirmation was obtained for the primary lesions of 29 of the 31 patients. In the remaining 2 patients, the final diagnosis was based on the clinical course. [18F]FAPI-74 PET scanning was performed 60min after the intravenous injection of [18F]FAPI-74 (240631 MBq). The [18F]FAPI-74 PET images were compared between the primary or local recurrent lesions of malignant tumors (n = 21) and nonmalignant lesions (n 5 8: type-B1 thymomas, granuloma, solitary fibrous tumor, and postoperative or posttherapeutic changes). The uptake and number of detected lesions on [18F]FAPI-74 PET were also compared with those on [18F]FDG PET for available patients (n = 19). Results: [18F]FAPI-74 PET showed higher uptake in primary lesions of various cancers than in nonmalignant lesions (median SUVmax, 9.39 [range, 1.83-25.28] vs. 3.49 [range, 2.21-15.58]; P = 0.053), but some of the nonmalignant lesions showed high uptake. [18F]FAPI-74 PET also showed significantly higher uptake than [18F]FDG PET (median SUVmax, 9.44 [range, 2.50-25.28] vs. 5.45 [range, 1.22-15.06] in primary lesions [P 5 0.010], 8.86 [range, 3.51-23.33] vs. 3.84 [range, 1.01-9.75] in lymph node metastases [P 5 0.002], and 6.39 [range, 0.55-12.78] vs. 1.88 [range, 0.73-8.35] in other metastases [P 5 0.046], respectively). In 6 patients, [18F]FAPI-74 PET detected more metastatic lesions than [18F]FDG PET. Conclusion: [18F]FAPI-74 PET showed higher uptake and detection rates in primary and metastatic lesions than did [18F]FDG PET. [18F]FAPI-74 PET is a promising novel diagnostic modality for various tumors, especially for precise staging before treatment, including characterization of tumor lesions before surgery. Moreover, 18F-labeled FAPI ligand might serve a higher demand in clinical care in the future.
DC.rights	© 2023 by the Society of Nuclear Medicine andMolecular Imaging.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	92496
citation_title	Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
citation_author	Watabe, Tadashi
	Naka, Sadahiro
	Tatsumi, Mitsuaki
	Kamiya, Takashi
	Kimura, Toru
	Shintani, Yasushi
	Abe, Kaori
	Miyake, Tomohiro
	Shimazu, Kenzo
	Kobayashi, Shogo
	Kurokawa, Yukinori
	Eguchi, Hidetoshi
	Doki, Yuichiro
	Inohara, Hidenori
	Kato, Hiroki
	Mori, Yuriko
	Cardinale, Jens
	Giesel, Frederik L.
citation_publisher	Society of Nuclear Medicine Inc.
citation_language	English
citation_date	2023-06-02
citation_journal_title	Journal of Nuclear Medicine
citation_volume	64
citation_issue	8
citation_firstpage	1225
citation_lastpage	1231
citation_doi	https://doi.org/10.2967/jnumed.123.265486
citation_public_url	https://hdl.handle.net/11094/92496

Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions

Link to primary information

Item Information

Show details